RIL
PTGX icon

Rothschild Investment LLC’s Protagonist Therapeutics PTGX Stock Holding History

Rothschild Investment LLC’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Sell
106
-1
-0.9% -$104 ﹤0.01% 1741
2026
Q1 		$11.3K Buy
107
+21
+24% +$1.86K ﹤0.01% 1636
2025
Q4 		$7.51K Buy
86
+1
+1% +$82 ﹤0.01% 1695
2025
Q3 		$5.65K Sell
85
-25
-23% -$1.42K ﹤0.01% 1661
2025
Q2 		$6.08K Buy
110
+15
+16% +$720 ﹤0.01% 1412
2025
Q1 		$4.59K Buy
95
+50
+111% +$2.1K ﹤0.01% 1478
2024
Q4 		$1.74K Sell
45
-5
-10% -$218 ﹤0.01% 1891
2024
Q3 		$2.25K Buy
50
+30
+150% +$1.21K ﹤0.01% 1660
2024
Q2 		$693 Buy
20
+15
+300% +$439 ﹤0.01% 1845
2024
Q1 		$145 Buy
+5
New +$136 ﹤0.01% 1938

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Rothschild Investment LLC's PTGX Position: Q2 2026 in Review

Rothschild Investment LLC reduced its Protagonist Therapeutics (PTGX) stake by 0.93% in Q2 2026, selling an estimated $104 and leaving 106 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #1741.

Rothschild Investment LLC first reported a position in PTGX in Q1 2024 and has held it in 10 quarters since. 134 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Rothschild Investment LLC held 106 shares of Protagonist Therapeutics worth $13K as of Q2 2026.
  • Rothschild Investment LLC sold 1 Protagonist Therapeutics share in Q2 2026, an estimated $104.
  • Protagonist Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1741 holding.
  • Rothschild Investment LLC first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 134 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.